Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.

Indirect comparisons suggest that infliximab or adalimumab may be preferred first-line agents, and ustekinumab a preferred second-line agent, for induction of remission in patients with moderate-severe CD. Head-to-head trials are warranted.